Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single ascending dose, multiple ascending dose, and food effect study of LMT503 in healthy subjects
NL-OMON59203Phase 1Not yet recruiting
- Sponsor
- Lmito Therapeutics
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of LMT503 (3 arms), sponsored by Lmito Therapeutics. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
LMT503
Beyond the preview
Go deeper on NL-OMON59203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59203.